About this trial
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Eligibility criteria
Qualifiers
Subjects should have suspected or confirmed cancer of the upper genital tract.
Participant will undergo surgery for tumour removal.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
McGill University
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborator